Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL

Lori A. Leslie, MD, Sejal Kothadia, MD, Ewelina Protomastro, MS, Patricia J Greenberg, Tracy Andrews, PhD, Ann McNeill, ANP, Hoshiyuki Iida, Alan P Skarbnik, MD, Xiao Yang, Pritish K. Bhattacharyya, MD, Kar Fai Chow, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, Tatyana A Feldman, MD, Andre Goy, MD

Blood (2017) 130 (Supplement 1): 4163.

https://doi.org/10.1182/blood.V130.Suppl_1.4163.4163

Published: 2017

Journal Articles

Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma

Andre Goy, MD, Tatyana A Feldman, MD, Lori A. Leslie, MD, Rima Panchal Panchal, Intern, Themba Nyirenda, PhD, Alan P Skarbnik, MD, Kara Yannotti, BSN, Joshua Zenreich, Colleen M Bejot, APN, Susan Stives, APN, Kar Fai Chow, MD, Pritish K. Bhattacharyya, MD, Xiao Yang, Ernest Richards, PhD

Blood (2017) 130 (Supplement 1): 2785.

https://doi.org/10.1182/blood.V130.Suppl_1.2785.2785

Published: 2017

Journal Articles

Interim or End of Treatment FGD-PET Complete Response Does Not Have Adequate Predictive Value in Mature T/NK Cell Lymphoma

Tatyana Feldman, MD, Larysa Sanchez, MD, Patrick Toth, MD, David Panush, MD, Lori A Leslie, MD, Alan P Skarbnik, MD, Anthony R. Mato, MD, Kar Fai Chow, MD, Ricardo Parrondo, MD, Veronica Mariotti, MD, Sejal Kothadia, MD, Zhen Wang, MD, Miguel Gonzalez, MD, Pritish K. Bhattacharyya, MD, Xiao Yang, MD PhD, Themba Nyirenda, PhD, Ewelina Protomastro, MS, Lori A. Leslie, MD, Andre Goy, MD

Blood (2016) 128 (22): 1813.

https://doi.org/10.1182/blood.V128.22.1813.1813

Published: 2016

Journal Articles

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Anthony R. Mato, MD MSCE, Kenneth A. Foon, MD, Tatyana Feldman, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Kar Fai Chow, MD, Marisa Valentinetti, BS, Mary Morin, BS, Kelly Azzollini, BS, Gabriella Magarelli, MS, Pritish K. Bhattacharyya, MD, Joshua Zenreich, BS, Christina Howlett, PharmD, BCOP, Lauren-Nicole Pascual, BS, Kara Yanotti, BSN, Sabrina Kdiry, BSN, David Porter, MD, Andre Goy, MD

Blood (2014) 124 (21): 4678.

https://doi.org/10.1182/blood.V124.21.4678.4678

Published: 2014

Journal Articles

Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma

Blood (2014) 124 (21): 3033.

https://doi.org/10.1182/blood.V124.21.3033.3033

Published: 2014

Journal Articles

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Tatyana Feldman, MD, Larysa Gromko, MD, Ewelina A Protomastro, MS, Lina Starovoitova, BS, Anthony R. Mato, MD MSCE, Chad Glisch, Mona Sadekh, MD, Benjamin Schoener, MD, Susan Stives, APN, Marisa Valentinetti, RN, Mary Timberg, APN, Pritish K. Bhattacharyya, MD, Kar Fai Chow, MD, Xiao Yang, MD PhD, Alan P Skarbnik, MD, Andre Goy, MD MS

Blood (2014) 124 (21): 1307.

https://doi.org/10.1182/blood.V124.21.1307.1307

Published: 2014

Journal Articles

Dose Intensive Induction Followed By Allogeneic Stem Cell Transplantation More Than Doubles Progression-Free and Overall Survival In “Double-Hit” Lymphoma (DHL)

Christina Howlett, PharmD, Andre Goy, MD, Tania Zielonka, Andrew L Pecora, MD, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L. Donato, MD, Mary Timberg, MSN, Gabriella Gadaleta, MSN, David H. Vesole, MD, PhD, Pritish M Bhattacharyya, MD, Kar Fai Chow, MD, Raihan Faroqui, BS, Maria Rosario, Anthony R Mato, MD, MSCE

Blood (2013) 122 (21): 2141.

https://doi.org/10.1182/blood.V122.21.2141.2141

Published: 2013

Journal Articles

Overview Of The Genomic Landscape Of High Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA Sequencing

Kai Wang, MD PhD, Michelle Nahas, PhD, Anthony R Mato, MD, MSCE, Amy L Donahue, MS, Jie He, PhD, Geoff A Otto, PhD, Doron Lipson, PhD, Roman Yelensky, PhD, Jeff Ross, MD, Phil Stephens, PhD, Kar Fai Chow, MD, Tania Zielonka, Pritish K. Bhattacharyya, MD, Ewelina Protomastro, BS, Tatyana Feldman, MD, Andrew L. Pecora, MD, Vincent Miller, MD, Andre Goy, MD

Blood (2013) 122 (21): 501.

https://doi.org/10.1182/blood.V122.21.501.501

Published: 2013

Journal Articles

Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome

Anthony R Mato, MD, James Greenberg, BS, Mary E Putt, PhD, ScD, K. Stephen Suh, PhD, Yvonne Remache, BA, BSN, Tania Zielonka, RDC, Kathryn Waksmundzki, BS, Ewelina A Protomastro, BA, Susan Stives, APN, Tatyana Feldman, MD, Pritish K. Bhattacharyya, MD, Xiao Yang, M.D. Ph.D, Kar Fai Chow, MD, Alex Campaiola, BSN, Andrew L Pecora, MD, Andre Goy, MD

Blood (2012) 120 (21): 1579.

https://doi.org/10.1182/blood.V120.21.1579.1579

Published: 2012

NARROW

Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL

Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma

Interim or End of Treatment FGD-PET Complete Response Does Not Have Adequate Predictive Value in Mature T/NK Cell Lymphoma

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Dose Intensive Induction Followed By Allogeneic Stem Cell Transplantation More Than Doubles Progression-Free and Overall Survival In “Double-Hit” Lymphoma (DHL)

Overview Of The Genomic Landscape Of High Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA Sequencing

Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only